Cerity Partners LLC Supernus Pharmaceuticals, Inc. Transaction History

Cerity Partners LLC

  • $44.7 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$27.11 - $35.17 $165,994 - $215,345
6,123 New
6,123 $208,000
Q1 2023

May 11, 2023
BUY
$34.93 - $42.03 $37,270 - $44,846
1,067 New
1,067 $38,000
Q4 2019

Feb 14, 2020
SELL
$19.93 - $29.13 $177,357 - $259,227
-8,899 Closed
0 $0
Q3 2019

Oct 30, 2019
SELL
$25.47 - $33.37 $7,870 - $10,311
-309 Reduced 3.36%
8,899 $245,000
Q2 2019

Aug 14, 2019
BUY
$29.96 - $38.87 $275,871 - $357,914
9,208 New
9,208 $304,000

Others Institutions Holding SUPN

# of Institutions
285
Shares Held
60.7M
Call Options Held
27.7K
Put Options Held
11.3K
View Full List

About SUPERNUS PHARMACEUTICALS, INC.

SUPN Quotes by TradingView
  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Cerity Partners LLC Portfolio

Follow Cerity Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cerity Partners LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email